DDInter299 DDInter1676
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Carfilzomib {u} (Compound) resembles {v} (Compound) Ritonavir
Carfilzomib {u} (Compound) binds {v} (Gene) PSMB8
Carfilzomib {u} (Compound) is included by {v} (Pharmacologic Class) Proteasome Inhibitors
Carfilzomib {u} (Compound) causes {v} (Side Effect) Headache
Carfilzomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tuberculin purified protein derivative
Carfilzomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tioguanine
Carfilzomib {u} may lead to a major life threatening interaction when taken with {v} Conestat alfa
Carfilzomib {u} may lead to a major life threatening interaction when taken with {v} Infliximab
Carfilzomib (Compound) resembles Ritonavir (Compound)
Carfilzomib (Compound) binds PSMB8 (Gene)
Carfilzomib (Compound) is included by Proteasome Inhibitors (Pharmacologic Class)
Carfilzomib (Compound) causes Headache (Side Effect)
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine
Carfilzomib may lead to a major life threatening interaction when taken with Conestat alfa
Carfilzomib may lead to a major life threatening interaction when taken with Infliximab